A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects
Healthy Adults
DRUG: Adagrasib|DRUG: Eltrombopag + adagrasib
Pharmacokinetics - AUC (adagrasib), Area under the plasma concentration-time curve (AUC) from time zero to infinity (AUCâˆž), Days 1 and 8|Pharmacokinetics - AUC (adagrasib), AUC from time zero to the last quantifiable concentration (AUClast), Days 1 and 8|Pharmacokinetics - Cmax (adagrasib), Maximum observed plasma concentration (Cmax), Days 1 and 8|Pharmacokinetics - Tmax (adagrasib), Time to reach Cmax (tmax), Days 1 and 8|Pharmacokinetics - t1/2 (adagrasib), Elimination half-life (t1/2), Days 1 and 8|Pharmacokinetics - CL/F (adagrasib), Apparent total plasma clearance (CL/F), Days 1 and 8|Pharmacokinetics - Vz/F (adagrasib), Apparent volume of distribution (Vz/F), Days 1 and 8
Adverse Events (AEs), Incidence and severity of AEs, Up to 8 weeks from screening
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects